Novo Nordisk A/S (NVO)

34.79
0.61 1.70
NYSE : Health Care
Prev Close 35.40
Open 34.96
Day Low/High 34.58 / 35.04
52 Wk Low/High 30.89 / 57.81
Volume 2.30M
Avg Volume 3.95M
Exchange NYSE
Shares Outstanding 2.60B
Market Cap 92.38B
EPS 2.00
Div & Yield 0.91 (2.60%)

Latest News

A Seismic Shift in Stock Picking: Cramer's 'Mad Money' Recap (Thursday 1/12/17)

A Seismic Shift in Stock Picking: Cramer's 'Mad Money' Recap (Thursday 1/12/17)

Amazon.com has all the qualities we really want from our stocks - now, says Jim Cramer.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Novo Nordisk A/S - NVO

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Novo Nordisk A/S - NVO

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Novo Nordisk A/S securities (NYSE:NVO) from April 30, 2015 through October 27, 2016, inclusive...

Stocks Off Session Lows as Pressure on Tech Shares and Financials Eases

Stocks Off Session Lows as Pressure on Tech Shares and Financials Eases

Wall Street comes off session lows by mid-afternoon Thursday as pressure on tech, health care and financial stocks eases.

Stocks at Session Lows as Tech, Drugmaker Names Sell Off

Stocks at Session Lows as Tech, Drugmaker Names Sell Off

The Nasdaq pulls back from a record high on Thursday as tech and drugmaker shares decline.

Stock Futures Hold Lower as Jobless Claims, Import Prices Rise

Stock Futures Hold Lower as Jobless Claims, Import Prices Rise

Stock futures hold lower on Thursday after weekly jobless claims rise and import prices climb.

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

4 Blue-Chip Health-Care Picks on Sale (and the Portfolio Is Up 163% Since 2006)

Demographic trends that boosted big gains in prior years haven't gone away.

Eli Lilly and Express Scripts Announce Program to Lower Insulin Prices to Avoid Mylan-Like Uproar

Eli Lilly and Express Scripts Announce Program to Lower Insulin Prices to Avoid Mylan-Like Uproar

Eli Lilly and Express Scripts are seeking to avoid potential bad press over high insulin prices.

Stop Listening to 'The Market'

Stop Listening to 'The Market'

Here are stocks with solid fundamentals at some of the best absolute entry points in years.

Novo Nordisk Is an Opportunity

Novo Nordisk Is an Opportunity

I bought the stock too early, but I am adding more.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXE, CECE, EMN, FC, NNI, PDCO, SAH, SAMG, WERN Downgrades: ATW, CERN, IPXL, NVO, OMCL, PHII, PHIIK, PLKI, SVT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

One World Trade Center To Glow Blue In Honor Of World Diabetes Day Tonight

One World Trade Center To Glow Blue In Honor Of World Diabetes Day Tonight

The American Diabetes Association, JDRF, The New York Stem Cell Foundation Research Institute and Novo Nordisk Inc. Unite in the Battle Against Diabetes

MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing

MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing

MannKind bulls -- the rainbow-hued unicorns of the investment world -- believe the company's marketing efforts will succeed. They're wrong.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.

European Drug Companies Get an Injection From Trump Victory

European Drug Companies Get an Injection From Trump Victory

The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.

NKE, AGN, NFLX: Jim Cramer's Views

NKE, AGN, NFLX: Jim Cramer's Views

Cramer shares his views on price war victims. Nike, Allergan and Netflix are among the stocks discussed.

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Roche's Haemophilia Drug Difficulties Has Rivals Looking for an Edge

Pfizer, Bayer, Shire are among rivals bracing for Roche's ACE910.

ZBH's Big Unjustified Price Correction

ZBH's Big Unjustified Price Correction

Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.

Cramer: How Bad Was Today? Let Us Count the Ways

Cramer: How Bad Was Today? Let Us Count the Ways

Today there was a virtual vacuum of good news in the stock market.

Cramer: With the Election Coming, Valeant's Problem Is Increasing

Cramer: With the Election Coming, Valeant's Problem Is Increasing

We have to ask: where is the cash flow to pay off the debt, if any important prices are rolled back?

Where'd All the Volatility Go?

Dollar's activity is eye-catching.

Cramer: Nike Is a Victim of Price Wars; There Will Be Others

Cramer: Nike Is a Victim of Price Wars; There Will Be Others

Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

Cramer: Investors Look at Merck, Wondering Why They Did Not Buy Qualcomm

In a "take no pain, take no prisoners" market, health care stocks languish.

European Stocks Mixed on Divergence in Economic Data, Mixed Earnings

European Stocks Mixed on Divergence in Economic Data, Mixed Earnings

Economic data in France disappoints; Germany and U.K. beat expectations.

Novo Nordisk Stock Plunges as U.S. Problems Cloud Outlook

Novo Nordisk Stock Plunges as U.S. Problems Cloud Outlook

The Danish drugs maker halves targets for operating profit growth.